Oramed Pharmaceuticals Inc. has successfully completed its acquisition of Oratech Pharma, Inc., a wholly-owned subsidiary, as part of a strategic move to enhance its operational capabilities and market presence. The acquisition was finalized on March 25, 2026, following the terms outlined in a Share Purchase Agreement signed on January 12, 2026. Under this agreement, Lifeward Ltd. acquired all outstanding equity interests in Oratech in exchange for a combination of Lifeward Ordinary Shares, pre-funded warrants, and revenue-sharing payments based on the net revenue from Lifeward's ReWalk Personal Exoskeleton products. This transaction is expected to bolster Oramed's revenue streams and expand its product offerings in the medical technology sector.

In conjunction with the acquisition, Oramed also closed a Securities Purchase Agreement with Lifeward, securing $9 million in senior secured convertible notes. These notes are convertible into Lifeward Ordinary Shares at an initial conversion price of $5.40 per share, which is subject to adjustments. The issuance of these notes, along with the associated warrants, is anticipated to provide Oramed with additional financial flexibility to support its growth initiatives.

The completion of these transactions marks a significant milestone for Oramed, positioning the company for future growth and innovation in the pharmaceutical industry. The strategic acquisition and financing efforts are expected to enhance shareholder value and drive long-term success.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.